| TAH Drug Code | IDOX |
|---|---|
| Indications | Acute and chronic leukocytosis, sarcoma, lymphoma, fibrosarcoma, neuroblastoma, breast cancer, lung cancer. |
| Dosing | Administer by intravenous injection or, for local tumor treatment, slow infusion through the local artery or instillation into the bladder via catheter. Dissolve using provided solvent. Do not administer orally, or via intramuscular or intrathecal injection. [Intravenous Injection] The cumulative dose of intravenous doxorubicin should not exceed 550 mg/m2. Monotherapy: (Adults) 60-75 mg/m2 IVD every 21 days. (Elderly or immunocompromised) 60 mg/m2 IVD every 21 days. (Pediatric) 30 mg/m2 IVD, administered daily for three consecutive days, repeated every 4 weeks. Combination Therapy: (With bone marrow suppressants) 25-50 mg/m2 IVD every 3-4 weeks. (Without bone marrow suppressants) 60-75 mg/m2 IVD every 3-4 weeks. [Intravesical Administration] Instill 30-50 mg into the bladder let it stay for 1-2 hours every 1 week to 1 month. Recommended concentration: 1 mg/mL. Rotate body during instillation for optimal contact. Instruct patients not to drink liquids 12 hours before to avoid dilution. Prompt voiding after instillation. |
| Hepatic Impairment | Dose adjustment required |
| Renal Impairment | Dose adjustment required |
| Contraindications | Allergic reaction to the main ingredient or other excipients. Allergic reaction to other anthracyclines or anthracenediones. Intravenous injection use: Previous persistent bone marrow suppression caused by other antineoplastic drugs or radiation therapy. Severe hepatic dysfunction. Severe myocardial dysfunction. Recent myocardial infarction. Severe arrhythmias. Previous treatment with the maximum cumulative dose of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones. Intravesical use: Urethral infection. Bladder inflammation. Hematuria. |
| Adverse Effects | Common: Alopecia (92%), Nausea (>10%), Vomiting (34-37%) Serious: Cardiomyopathy, Congestive heart failure, Left ventricular failure, acute, Myocardial infarction, Myocarditis, Pericarditis, Tachyarrhythmia, Injection site extravasation, Radiation recall reaction due to cytotoxic therapy, Tissue necrosis, Pancreatitis, Acute myeloid leukemia, Leukopenia, Grade 3 or 4 (3.7%), Myelodysplastic syndrome, Myelosuppression, Neutropenia, Thrombocytopenia, Grade 3 or 4 (0.1%), Hepatitis, Veno-occlusive disease of the liver, Anaphylaxis, Septic shock (2%), Radiation pneumonitis, Tumor lysis syndrome |
| Pregnancy | Contraindicated – 1st Trimester |
| Lactation | Contraindicated |
| More Info | UpToDate |